Oppenheimer & Co. Inc. Acquires 92 Shares of Chemed Co. (NYSE:CHE)

Oppenheimer & Co. Inc. raised its holdings in Chemed Co. (NYSE:CHE) by 0.7% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 13,277 shares of the company’s stock after acquiring an additional 92 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Chemed were worth $7,979,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. EntryPoint Capital LLC boosted its stake in Chemed by 14.0% during the first quarter. EntryPoint Capital LLC now owns 147 shares of the company’s stock worth $94,000 after acquiring an additional 18 shares in the last quarter. Covestor Ltd boosted its position in shares of Chemed by 10.6% during the 1st quarter. Covestor Ltd now owns 219 shares of the company’s stock worth $141,000 after purchasing an additional 21 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Chemed by 34.4% in the 2nd quarter. GAMMA Investing LLC now owns 86 shares of the company’s stock valued at $47,000 after buying an additional 22 shares during the period. Ballentine Partners LLC grew its stake in shares of Chemed by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 655 shares of the company’s stock valued at $394,000 after buying an additional 26 shares during the period. Finally, Everpar Advisors LLC increased its position in Chemed by 4.9% in the 2nd quarter. Everpar Advisors LLC now owns 580 shares of the company’s stock valued at $315,000 after buying an additional 27 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Trading Down 0.0 %

CHE opened at $565.37 on Thursday. Chemed Co. has a 1-year low of $523.33 and a 1-year high of $654.62. The company has a market cap of $8.51 billion, a price-to-earnings ratio of 28.57, a PEG ratio of 2.40 and a beta of 0.46. The company’s fifty day moving average price is $580.85 and its two-hundred day moving average price is $565.47.

Chemed (NYSE:CHE) last posted its earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing analysts’ consensus estimates of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. During the same quarter in the prior year, the company earned $5.32 EPS. The company’s revenue was up 7.4% on a year-over-year basis. As a group, equities analysts forecast that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Monday, November 18th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $2.00 annualized dividend and a dividend yield of 0.35%. Chemed’s payout ratio is 10.11%.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada cut their price target on Chemed from $697.00 to $633.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th.

Insider Buying and Selling

In other news, Director Andrea R. Lindell sold 831 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $571.51, for a total value of $474,924.81. Following the completion of the sale, the director now owns 5,725 shares in the company, valued at $3,271,894.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director George J. Walsh III sold 200 shares of Chemed stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $577.95, for a total transaction of $115,590.00. Following the sale, the director now directly owns 3,446 shares in the company, valued at $1,991,615.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrea R. Lindell sold 831 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $571.51, for a total transaction of $474,924.81. Following the transaction, the director now owns 5,725 shares of the company’s stock, valued at approximately $3,271,894.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,144 shares of company stock worth $3,002,419. 3.32% of the stock is owned by corporate insiders.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.